netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Medi found 131 matches

Formulary items 64 matches
Sub Section Title / notes 12  matches
   
Open monograph to display formulary status BNF Category
  Betamethasone (as valerate) Medicated plasters  (Betesil®) Skin - Potent - 13.04
  Lidocaine 5% Medicated plasters (700mg lidocaine/plaster) Central nervous system - Postherpetic neuralgia - 04.07.03
  Medi Derma® S
(Barrier Cream) 		Wound Care - Other Wound Products - 18.10
  Medi Derma® S
(Barrier Film) 		Wound Care - Other Wound Products - 18.10
  Medi Derma-Pro Foam & Spray Skin Cleanser And Skin Protectant Ointment   (Medi Derma-Pro Foam & Spray Skin Cleanser®) Skin - Barrier preparations - 13.02.02
  Medi Derma-S barrier film   (Medi Derma-S ®barrier film) Skin - Barrier preparations - 13.02.02
  Medi® hosiery
(UNDER REVIEW) 		Wound Care - Graduated compression hosiery - 18.09.01
  Mediscrub® Skin - Cationic surfactants and soaps - 13.11.03
  NaldeMedine  (Rizmoic®) Gastro-intestinal system - Peripheral opioid-receptor antagonist - 01.06.06
  Acetylcysteine
(Mucolytic) 		Respiratory system - Mucolytics - 03.07
  Algivon® Wound Care - Sheet dressing - 18.03.01
  Anusol ® Gastro-intestinal system - Soothing haemorrhoidal preparations - 01.07.01
  Anusol®HC
(Ointment / Suppositories) 		Gastro-intestinal system - Compound haemorrhoidal preparations with corticosteroids - 01.07.02
  Artificial Saliva Ear, nose and oropharynx - Treatment of dry mouth - 12.03.05
  Brinzolamide 10mg/ml & brimonidine 2mg/ml  (Simbrinza®) Eye - Carbonic anhydrase inhibitors and systemic drugs - 11.06
  Capreomycin Infections - Antituberculosis drugs - 05.01.09
  Cefazolin Infections - Cephalosporins - 05.01.02.01
  Chlorhexidine Ear, nose and oropharynx - Mouthwashes, gargles, and dentifrices - 12.03.04
  Clozapine Central nervous system - Second Generation Antipsychotic Drugs - 04.02.01
  Controlled Drug Dihydrocodeine Central nervous system - Opioid analgesics - 04.07.02
  Eliglustat  (Cerdelga®) Nutrition and blood - Drugs used in metabolic disorders - 09.08.01
  Estradiol valerate plus dienogest  (Qlaira®) Obstetrics, Gynaecology, and urinary-tract disorders - Combined hormonal contraceptives - 07.03.01
  Fenfluramine  (Fintepla®) Central nervous system - Control of epilepsy - 04.08.01
  Gadobutrol  (Gadovist®) Miscellaneous Preparations [non-BNF and Unlicensed Drugs] - MRI Contrast Media - 19
  Gadoxetic acid  (Primovist®) Miscellaneous Preparations [non-BNF and Unlicensed Drugs] - MRI Contrast Media - 19
  Gastrografin Miscellaneous Preparations [non-BNF and Unlicensed Drugs] - MRI Contrast Media - 19
  Haemorrhoid relief ointment Gastro-intestinal system - Soothing haemorrhoidal preparations - 01.07.01
  Hydrocortisone modified-release capsules  (Efmody®) Endocrine system - Glucocorticoid therapy - 06.03.02
  Imiquimod 5% cream  (Aldara®) Skin - Anogenital warts - 13.07
  Iopanoic acid Endocrine system - Antithyroid drugs - 06.02.02
  Landiolol Cardiovascular system - Beta-adrenoceptor blocking drugs - 02.04
  Lisocabtagene maraleucel  (Breyanzi®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
  L-Mesitran® Ointment Wound Care - Honey-based topical application - 18.03.01
  L-Mesitran® Ointment S Wound Care - Honey-based topical application - 18.03.01
  Meglumine gadoterate  (Dotarem®) Miscellaneous Preparations [non-BNF and Unlicensed Drugs] - MRI Contrast Media - 19
  Controlled Drug Methylphenidate Central nervous system - CNS stimulants and other drugs used for attention deficit hyperactivity disorder - 04.04
  Midazolam Anaesthesia - Benzodiazepines - 15.01.04.01
  Controlled Drug Morphine Central nervous system - Opioid analgesics - 04.07.02
  Oxybutynin Obstetrics, Gynaecology, and urinary-tract disorders - Urinary incontinence - 07.04.02
  Controlled Drug Oxycodone Central nervous system - Opioid analgesics - 04.07.02
  Controlled Drug Oxycodone
(palliative care) 		Palliative Care Formulary - Pain - 21.01
  Phenazone with lidocaine  (Otigo®) Ear, nose and oropharynx - Otitis media - 12.01.02
  Potassium Iodate 85mg tablets Endocrine system - Antithyroid drugs - 06.02.02
  Proctosedyl® Gastro-intestinal system - Compound haemorrhoidal preparations with corticosteroids - 01.07.02
  Quetiapine Central nervous system - Second Generation Antipsychotic Drugs - 04.02.01
  Relugolix–estradiol–norethisterone acetate  (Ryeqo®) Endocrine system - Drugs affecting gonadotrophins - 06.07.02
  Rituximab Malignant disease and immunosuppression - Anti-lymphocyte monoclonal antibodies - 08.02.03
  Rivastigmine Central nervous system - Drugs for dementia - 04.11
  Scheriproct®
(Ointment / Suppositories) 		Gastro-intestinal system - Compound haemorrhoidal preparations with corticosteroids - 01.07.02
  Semaglutide Endocrine system - GLP1 agonists - 06.01.02.03
  Simeticone  (Infacol® Dentinox®) Gastro-intestinal system - Simeticine alone - 01.01.01
  Sodium Fluoride Nutrition and blood - Fluoride - 09.05.03
  Sodium Fluoride
(palliative care) 		Palliative Care Formulary - Other - 21.07
  Sodium Valproate
(Category 2) 		Central nervous system - Control of epilepsy - 04.08.01
  Sodium valproate  (Epilim Chrono®) Central nervous system - Valproic acid - 04.02.03
  Sodium valproate  (migraine) Central nervous system - Prophylaxis of migraine - 04.07.04.02
  Sodium Valproate Injection Central nervous system - Control of epilepsy - 04.08.01
  Sodium zirconium cyclosilicate  (Lokelma®) Nutrition and blood - Potassium removal - 09.02.01.01
  Spironolactone Cardiovascular system - Aldosterone antagonists - 02.02.03
  Strontium Ranelate
(Sachets) 		Endocrine system - Strontium renelate - 06.06.02
  Tirzepatide  (Mounjaro®) Endocrine system - GLP1 agonists - 06.01.02.03
  Ulipristal  (Esmya®) Endocrine system - Progestogens - 06.04.01.02
  Valproic Acid  (Depakote®)
(Semisodium valproate) 		Central nervous system - Valproic acid - 04.02.03
  Voretigene neparvovec  (Luxturna®) Eye - Ocular diagnostic and peri-operative preparations and photodynamic treatment - 11.08.02
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section Clinical Commissioning Policy: Pasireotide diaspartate: an injectable medical therapy for the treatment of Cushings’ Disease (08.03.04.03)
link in drug section DHSC Medicine Supply Notification - Permethrin 5% w/w cream (13.10.04)
link in drug section MHRA Drug Safety Alert (Nov 2017): Quinine: reminder of dose-dependent QT-prolonging effects; updated medicine interactions (05.04.01)
link in drug section MHRA Drug Safety Alert (Nov 2017): Quinine: reminder of dose-dependent QT-prolonging effects; updated medicine interactions (05.04.01)
link in drug section MHRA Drug Safety Alert (Oct 2017): Methylprednisolone injectable medicine containing lactose (Solu-Medrone 40 mg): do not use in patients with cows’ milk allergy  (06.03.02)
link in drug section MHRA Drug Safety Update (Dec 2014): Smoking and smoking cessation: clinically significant interactions with commonly used medicines (03.01.03)
link in drug section MHRA Drug Safety Update (December 2014) Cabazitaxel (Jevtana▼): risk of medication error resulting in overdose (08.01.05)
link in drug section MHRA Drug Safety Update (Feb 2020): Lemtrada▼ (alemtuzumab): updated restrictions and strengthened monitoring requirements following review of serious cardiovascular and immune-mediated reactions (08.02.03)
link in drug section MHRA Drug Safety Update (Feb 2020): Lemtrada▼ (alemtuzumab): updated restrictions and strengthened monitoring requirements following review of serious cardiovascular and immune-mediated reactions (08.02.03)
link in drug section MHRA Drug Safety Update (February 2024): Codeine linctus (codeine oral solutions): reclassification to prescription-only medicine (21.01)
link in drug section MHRA Drug Safety Update (February 2024): Codeine linctus (codeine oral solutions): reclassification to prescription-only medicine (03.09.01)
link in drug section MHRA Drug Safety Update (Jan 2019): Tapentadol (Palexia): risk of seizures and reports of serotonin syndrome when co-administered with other medicines (04.07.02)
link in drug section MHRA Drug Safety Update (Jan 2021): SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery (04.03.03)
link in drug section MHRA Drug Safety Update (Jan 2021): SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery (04.03.03)
link in drug section MHRA Drug Safety Update (Jan 2021): SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery (04.03.03)
link in drug section MHRA Drug Safety Update (Jan 2021): SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery (04.03.03)
link in drug section MHRA Drug Safety Update (Jan 2021): SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery (04.03.03)
link in drug section MHRA Drug Safety Update (Jan 2022): Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error (08.01.05)
link in drug section MHRA Drug Safety Update (Jan 2022): Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error (08.01.05)
link in drug section MHRA Drug Safety Update (July 2020): Liposomal and lipid- complex formulations: name change to reduce medication errors (08.01.03)
link in drug section MHRA Drug Safety Update (July 2020): Liposomal and lipid- complex formulations: name change to reduce medication errors (05.02.03)
link in drug section MHRA Drug Safety Update (July 2020): Liposomal and lipid- complex formulations: name change to reduce medication errors (08.01.02)
link in drug section MHRA Drug Safety Update (July 2021): Oral retinoid medicines (isotretinoin▼, alitretinoin▼, and acitretin▼): temporary monitoring advice during coronavirus (COVID-19) pandemic (13.05.01)
link in drug section MHRA Drug Safety Update (July 2021): Oral retinoid medicines (isotretinoin▼, alitretinoin▼, and acitretin▼): temporary monitoring advice during coronavirus (COVID-19) pandemic (13.05.02)
link in drug section MHRA Drug Safety Update (Jun 2019): Oral retinoid medicines▼: revised and simplified pregnancy prevention educational materials for healthcare professionals and women (13.05.02)
link in drug section MHRA Drug Safety Update (Jun 2019): Oral retinoid medicines▼: revised and simplified pregnancy prevention educational materials for healthcare professionals and women (13.05.01)
link in subsection MHRA Drug Safety Update (June 2014): Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function—new warnings (02.05.05.01)
link in subsection MHRA Drug Safety Update (June 2014): Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function—new warnings (02.05.05.03)
link in subsection MHRA Drug Safety Update (June 2014): Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function—new warnings (02.05.05.02)
link in subsection MHRA Drug Safety Update (June 2014): Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function—new warnings (02.05.05)
link in drug section MHRA Drug Safety Update (March 2014): Orlistat: theoretical interaction with antiretroviral HIV medicines (04.05.01)
link in drug section MHRA Drug Safety Update (May 2019): Lemtrada (alemtuzumab) and serious cardiovascular and immune- mediated adverse reactions: new restrictions to use and strengthened monitoring requirements (08.02.03)
link in drug section MHRA Drug Safety Update (May 2019): Lemtrada (alemtuzumab) and serious cardiovascular and immune- mediated adverse reactions: new restrictions to use and strengthened monitoring requirements (08.02.03)
link in subsection MHRA Drug Safety Updates: Antiretroviral Medicines (05.03.01)
link in subsection NENC Management of COPD Exacerbations – Rescue medication in primary care (Master)
link in drug section NICE NG144: Cannabis-based medicinal products (10.02.02)
link in subsection NICE NG15: Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use (Master)
link in subsection NICE NG233: Otitis media with effusion in under 12s (12.01.02)
link in subsection NICE NG91: Otitis media (acute): antimicrobial prescribing (12.01.02)
link in drug section NICE TA651 - Naldemedine for treating opioid-induced constipation (01.06.06)
link in drug section NICE TA872: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (08.01.05)
link in subsection North East and North Cumbria ICS - Medication Management of Type 2 Diabetes in Adults Guidelines (06.01)
link in drug section RCPCH & NPPG Position Statement - Using Standardised Concentrations of Liquid Medicines in Children (09.02.01.02)
link in drug section RCPCH Position Statement: Using Standardised Concentrations of Liquid Medicines in Children (02.02.03)
link in drug section RDTC Medicines in Practice: Docusate for constipation (login required)  (01.06.02)
link in drug section Regional Medicines Optimisation Committee (RMOC) Position Statement Oral vitamin B supplementation in alcoholism and other indications e.g. refeeding syndrome - November 2019 (09.06.02)
link in subsection TEWV - Medicines Optimisation – Interactive Guide (Master)
link in drug section TEWV Depression medication pathway for adults (04.03.04)
link in subsection TEWV Depression medication pathway for adults (04.03)
link in drug section TEWV Depression medication pathway for adults (04.03.04)
link in subsection TEWV: Anxiety medication pathway for adults (04.01.02)
link in drug section Valproate medicines: Pregnancy Prevention Programme materials (04.07.04.02)
link in drug section Valproate medicines: Pregnancy Prevention Programme materials (04.08.01)
link in drug section Valproate medicines: Pregnancy Prevention Programme materials (04.02.03)
link in drug section Valproate medicines: Pregnancy Prevention Programme materials (04.02.03)

SubSection Titles / notes  
Antifungals - (11.03.02)
Contact lenses - (11.09)
Emollient bath and shower preparations - (13.02.01.01)
InterMediate- and long-acting insulins - (06.01.01.02)
Medicated bandages - (18.08.09)
Medicated stocking - (18.08.09)
MRI Contrast Media - (19)
Neuropathic pain - (04.07.03)
Opioid analgesics - (04.07.02)
Otitis Media - (12.01.02)
SomatoMedins - (06.07.04)
Sunscreen preparations - (13.08.01)

 
netFormulary